Try our beta test site
35 studies found for:    (lymphoma [CONDITION] OR CLL [CONDITION]) AND Lenalidomide AND Rituxan [TREATMENT] | Open Studies
Show Display Options
Rank Status Study
1 Recruiting Lenalidomide and Rituximab in Subjects With Previously Untreated Indolent Non-Hodgkin's Lymphoma
Interventions: Drug: Rituximab;   Drug: Lenalidomide
2 Recruiting Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.
Interventions: Drug: Lenalidomide;   Drug: Rituximab
3 Not yet recruiting Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma
Interventions: Drug: Ixazomib;   Drug: Lenalidomide;   Drug: Rituximab
4 Recruiting Phase I/II Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma
Interventions: Drug: Carfilzomib;   Drug: Lenalidomide;   Drug: Rituximab
5 Recruiting Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)
Interventions: Drug: Rituximab;   Drug: Lenalidomide;   Drug: Placebo
6 Recruiting Safety and Efficacy of Revlimid® (Lenalidomide) With Mabthera® (Rituximab) in Non-Hodgkin's Lymphoma
Intervention: Drug: Lenalidomide/Rituximab
7 Recruiting Study of Ibrutinib in Combination With Rituximab and Lenalidomide in Previously Untreated Subjects With Follicular Lymphoma and Marginal Zone Lymphoma
Interventions: Drug: Lenalidomide;   Drug: Rituximab;   Drug: Ibrutinib
8 Recruiting A Combination of Lenalidomide and Rituximab as Front Line Therapy for the Treatment of Elderly Frail Patients Evaluated in CGA With Diffuse Large B-cells Non-Hodgkin Lymphoma. A Phase II Study of the Fondazione Italiana Linfomi (FIL)
Intervention: Drug: Rituximab-Dexamethasone-Lenalidomide
9 Recruiting Lenalidomide Plus Rituximab for Recurrent/Refractory CNS and Intraocular Lymphoma
Interventions: Drug: Lenalidomide;   Drug: Rituximab
10 Recruiting Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (THRiL) as Initial Treatment for Patients With CLL
Interventions: Drug: thalidomide;   Drug: lenalidomide;   Biological: rituximab
11 Recruiting Study of Rituximab, Lenalidomide, and Ibrutinib Combined With Chemotherapy For Patients With High Risk Diffuse Large B-Cell Lymphoma
Interventions: Drug: Rituximab;   Drug: Ibrutinib;   Drug: Lenalidomide;   Drug: Etoposide;   Drug: Prednisone;   Drug: Vincristine;   Drug: Cyclophosphamide;   Drug: Doxorubicin
12 Recruiting Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-Bendamustine for Relapsed/Refractory FL Patients
Interventions: Drug: R2-MANT;   Drug: R-MANT
13 Recruiting Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab (Rituxan®) and Lenalidomide (Revlimid®) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)
Interventions: Drug: Bendamustine Hydrochloride;   Drug: Rituximab;   Drug: Lenalidomid
14 Recruiting Efficacy of Lenalidomide in Combination With Subcutaneous Rituximab + miniCHOP in DLBCL Patients of 80 y/o or+
Interventions: Drug: Lenalidomide;   Drug: Rituximab
15 Recruiting R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL
Interventions: Drug: R-CHOP;   Drug: R-CHOP / R-HAD;   Drug: Rituximab;   Drug: Lenalidomide
16 Recruiting A Trial of Ibrutinib, Lenalidomide and Rituximab for Patients With Relapsed/Refractory Mantle Cell Lymphoma
Interventions: Drug: Lenalidomide;   Drug: Ibrutinib;   Drug: Rituximab
17 Recruiting Dose Finding Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Interventions: Drug: Lenalidomide;   Drug: Ibrutinib;   Drug: Rituximab
18 Recruiting Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Interventions: Drug: Ibrutinib;   Drug: Lenalidomide;   Drug: Rituximab
19 Recruiting Lenalidomide, MTX, Ara-C and Rituximab in Relapsed Aggressive B-cell Lymphomas
Intervention: Drug: Lenalidomide
20 Recruiting Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma
Interventions: Drug: Lenalidomide;   Drug: R-CHOP;   Drug: high-dose cytarabine (HIDAC)

   Previous Page Studies Shown (1-20) Next Page (21-35) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.